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Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149S1442-tailed t-test P ¼ .74, Figure 1A). Results depend on the type
of transplant received, however, as MUD transplants showed
a differential expression in serum uric acid levels between
the two groups (2.64mg/dl for aGVHD+ vs. 2.18 for aGVHD-,
P ¼ .047, Figure 1B), while MRD transplants did not show
a difference (2.97mg/dl for aGVHD+ vs. 2.98 for aGVHD-, P ¼
.95, Figure 1C). Patients given rasburicase had a lower serum
uric acid level compared to the control arm (0.213mg/dl vs.
3.04 for d-7 to -2; 1.20mg/dl vs. 2.85 over all days, P < .0001)
as well as signiﬁcantly less aGVHD (rasburicase: 22% vs.
control: 48%, Fisher's exact test, P ¼ .033). Lower serum uric
acid level at the time of transplantation appears to be
protective against the development of aGVHD among
patients receiving matched unrelated donor transplants.
Rasburicase, when administered during the conditioning,
signiﬁcantly lowers the serum uric acid level and appears to
decrease aGVHD.
Figure 1. Mean uric acid levels from day-7 to day+6 between control patients
who developed aGVHD2+ (Red) vs. no aGVHD2+ (Blue).HEMATOPOIESIS/MESENCHYMAL CELLS ORAL
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Introduction: Despite improvements in the last decade in
the ﬁeld of HSCT, acute graft versus host disease (aGVHD)
remains a life-threatening complication of HSCT. In partic-
ular, the outcome of patients with severe steroid-resistant
aGVHD is very poor. Therefore, it remains important to
search for new therapeutic strategies.
Objective: The feasibility of the generation ofMSCs expanded
with platelet lysate (PL) was tested as well as the feasibility
and safety of the application in patients with steroid-refrac-
tory aGVHD. Immunological changes after infusion of MSC
were characterized, in vitro. However, truly active mecha-
nisms in human are poorly understood as well as whether
infusion of MSC selectively impairs GVHD-inducing immune
cells or also anti-virus and anti-leukemia reactive T-cells.Phenotypical and functional changes in immunological cell
types and cytokine levels were investigated.
Method: In an open-label, non-randomized prospective
phase I/II study MSCs from the bone marrow of healthy
volunteers, expanded with PL. Patients with steroid-refrac-
tory aGVHD grade II-IV were treated with PL-MSC. 50
patients were included and received up to 4 infusions.
Response rate, transplantation-related deaths, and other
adverse events were assessed for up to 12 months after
inclusion. In addition, a comprehensive phenotypical and
functional analysis was performed with PBMCs and serum
isolated from all patients before, during, and after infusion of
MSC.
Results: Between 2009-2012, 50 patients were included, 2
dropped out, 5 are so far incompletely documented. Thus 43
were available for analysis, 6 children and 37 adults. Median
age was 51,5 yr (1.3-65.9). Organs involved in aGVHD were
skin (56%), gi-tract (86%) and liver (33%). Overall grade was II
26%, III 65%, and IV 7%. Mean number of infusion were 3 (1-
4). No severe side effects were observed. Median follow-up
was 4 months (0.4-12). Complete overall response was
observed in 56% patients after a median of 53 days (3-116).
The overall survival was signiﬁcantly better in responders
when compared to non-responders (p <0.001). Immuno-
logical monitoring suggests that anti-viral and anti-leukemia
reactive T-cells are well preserved in all patients who
responded to MSC treatment. In addition, we identiﬁed
biomarkers which associate even 2 weeks after MSC infusion
with complete resolution of GVHD.
Conclusion: Generation and infusion of PL-MSCs in steroid-
resistant aGVHD grade II- IV is feasible, safe and is effective.
In addition, also patients who initially responded to PL-MSCs
but develop later a relapse of aGVHD during tapering or
cessation of immunosuppressive drugs become again sensi-
tive to the treatment with steroids. Infusion of MSC did not
impair anti-virus and anti-leukemia reactive T-cells. Identi-
ﬁed biomarkers predict very early a usually late clinical
resolution of GVHD, thus might be useful.HISTOCOMPATIBILITY/ALTERNATIVE STEM CELL SOURCES
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Background: Retrospective studies suggest that double-unit
cord blood (CB) grafts may improve engraftment and protect
against relapse as compared with that observed after single-
unit CB transplantation (CBT). However, whether the
